ANTITHROMBOCYTIC THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC STROKE
Approaches to preventing recurrent stroke by antithrombocytic therapy are shown to be as diverse as its causes. The diagnosis of cardioembolic stroke in patients with atrial fibrillation should not limit the choice of an antithrombocytic agent to only oral (indirect) anticoagulants (OAC). If OAC can...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2009-12-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/356 |
| _version_ | 1797876567146233856 |
|---|---|
| author | A. V. Fonyakin L. A. Geraskina |
| author_facet | A. V. Fonyakin L. A. Geraskina |
| author_sort | A. V. Fonyakin |
| collection | DOAJ |
| description | Approaches to preventing recurrent stroke by antithrombocytic therapy are shown to be as diverse as its causes. The diagnosis of cardioembolic stroke in patients with atrial fibrillation should not limit the choice of an antithrombocytic agent to only oral (indirect) anticoagulants (OAC). If OAC cannot be used, antithrombocytic therapy, including combined (clopidogrel + ASA) one, may be considered as a reasonable alternative. Approaches to choosing the optimal antithrombocytic drug in noncardioembolic strokes are intricate since atherosclerosis is a systemic vascular disease and the poststroke period is characterized by a higher risk for not only recurrent stroke, but also for coronary catastrophes. It is concluded that an antithrombocytic agent should be chosen, by taking into account the multifocality of atherosclerosis, associated clinical conditions, diabetes mellitus, intravascular interventions and the individual risk of all cardiovascular events. |
| first_indexed | 2024-04-10T02:05:19Z |
| format | Article |
| id | doaj.art-5c1fc28e0c584f5b89f0647c8097bea2 |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2024-04-10T02:05:19Z |
| publishDate | 2009-12-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-5c1fc28e0c584f5b89f0647c8097bea22023-03-13T08:42:10ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422009-12-0113-4586310.14412/2074-2711-2009-57356ANTITHROMBOCYTIC THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC STROKEA. V. Fonyakin0L. A. Geraskina1Neurology Research Center, Russian Academy of Medical SciencesNeurology Research Center, Russian Academy of Medical SciencesApproaches to preventing recurrent stroke by antithrombocytic therapy are shown to be as diverse as its causes. The diagnosis of cardioembolic stroke in patients with atrial fibrillation should not limit the choice of an antithrombocytic agent to only oral (indirect) anticoagulants (OAC). If OAC cannot be used, antithrombocytic therapy, including combined (clopidogrel + ASA) one, may be considered as a reasonable alternative. Approaches to choosing the optimal antithrombocytic drug in noncardioembolic strokes are intricate since atherosclerosis is a systemic vascular disease and the poststroke period is characterized by a higher risk for not only recurrent stroke, but also for coronary catastrophes. It is concluded that an antithrombocytic agent should be chosen, by taking into account the multifocality of atherosclerosis, associated clinical conditions, diabetes mellitus, intravascular interventions and the individual risk of all cardiovascular events.https://nnp.ima-press.net/nnp/article/view/356ischemic strokesecondary preventionantithrombotic therapy |
| spellingShingle | A. V. Fonyakin L. A. Geraskina ANTITHROMBOCYTIC THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC STROKE Неврология, нейропсихиатрия, психосоматика ischemic stroke secondary prevention antithrombotic therapy |
| title | ANTITHROMBOCYTIC THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC STROKE |
| title_full | ANTITHROMBOCYTIC THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC STROKE |
| title_fullStr | ANTITHROMBOCYTIC THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC STROKE |
| title_full_unstemmed | ANTITHROMBOCYTIC THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC STROKE |
| title_short | ANTITHROMBOCYTIC THERAPY IN THE SECONDARY PREVENTION OF ISCHEMIC STROKE |
| title_sort | antithrombocytic therapy in the secondary prevention of ischemic stroke |
| topic | ischemic stroke secondary prevention antithrombotic therapy |
| url | https://nnp.ima-press.net/nnp/article/view/356 |
| work_keys_str_mv | AT avfonyakin antithrombocytictherapyinthesecondarypreventionofischemicstroke AT lageraskina antithrombocytictherapyinthesecondarypreventionofischemicstroke |